BBIO News and Press, BridgeBio Pharma Inc. From 05/04/23

2023-05-04 10:08:25 ET BridgeBio Pharma press release ( NASDAQ: BBIO ): Q1 GAAP EPS of -$0.92. Revenue of $1.83M (+8.3% Y/Y). For further details see: BridgeBio Pharma GAAP EPS of -$0.92, revenue of $1.83M

- Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) has now completed last patient last visit and remains on track for topline month 30 registrational data to be announced in late July 2023 - Positive results announced in Cohort 5...

PALO ALTO, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will pr...

2023-04-24 05:31:06 ET Summary Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. Biotech deal-making has been increasing, with large acquisitions such as Pfizer's acquisit...

2023-04-19 09:35:00 ET Evercore ISI has initiated coverage of BridgeBio Pharma ( NASDAQ: BBIO ) with an outperform rating saying that two of its candidates are "potential blockbusters." The firm has a $40 price target (~164% upside based on Tuesday's close). Shares are...

2023-04-19 08:38:04 ET Intuitive Machines ( LUNR ) +24% up 24% as JV with KBR bags a $719M NASA contract. VYNE Therapeutics  ( VYNE ) +21% a nnounces positive Preclinical data for inhaled formulation of VYN201 in an in Vivo model of idiopathic pulmonary fibrosis...

2023-04-10 16:03:39 ET BridgeBio Pharma ( NASDAQ: BBIO ), a drug developer targeting genetic diseases, lost ~4% on Monday after a few leading members of its management team, including its chief executive, sold more than $2M worth of company shares. According to two separat...

2023-04-03 10:00:00 ET Growth stocks may have struggled over the past year, but a select few names have defied this broad downward trend in growth equities. Within healthcare, pharma companies developing cutting-edge medicines have been a particular bright spot. Several companies with n...

2023-04-02 16:32:28 ET Apellis Pharmaceuticals ( NASDAQ: APLS ) has attracted takeover interest from large pharmaceutical companies. The biotech firm that's focused on rare diseases and opthalmology is talking to advisers to consider its options, according to a ...

2023-03-29 12:12:50 ET BridgeBio Pharma ( NASDAQ: BBIO ), a potential buyout target, added ~18% on Wednesday, recording the second-best intraday gain for the year, amid market rumors that the company has decided to pull out of a conference next week. BridgeBio ( BBIO...